<DOC>
	<DOCNO>NCT01874002</DOCNO>
	<brief_summary>Patients stenosis one coronary artery often treat percutaneous coronary intervention ( PCI ) . As part PCI treatment stent often place keep vessel open time . The Combo-Stent novel stent use percutaneous angioplasty . In short , Combo stent combine drug elute technique endothelial cell attract layer . The drug coating design prevent re-narrowing stent . The endothelial cell attract layer design ensure rapid coverage stent strut vascular wall cell . The REMEDEE REGISTRY evaluate long-term safety performance Combo stent routine clinical practice . In total 1000 patient register followed five year .</brief_summary>
	<brief_title>Prospective Registry Asses Long-term Safety Performance Combo Stent</brief_title>
	<detailed_description>Registry Investigated Device : The OrbusNeich Combo Bio-engineered Sirolimus Eluting Stent ( Combo Stent ) consist 316L stainless steel alloy abluminally coat biocompatible , biodegradable polymer contain sirolimus . Covalently attach matrix layer murine , monoclonal , anti-human CD34 antibody . The antibody specifically target CD34+ cell circulation . Endothelial progenitor cell ( EPCs ) CD34+ . The stent supply premounted 0.014 '' guide wire compatible low profile rapid exchange balloon catheter delivery system . The Combo Stent Conformitée Européenne ( CE ) mark . Registry Objectives : The REMEDEE REGISTRY evaluate long term safety performance Abluminal Sirolimus Coated Bio-Engineered Stent ( Combo Bio-Engineered Sirolimus Eluting Stent ) routine clinical practice . The primary objective registry evaluate one year incidence target lesion failure consecutive patient undergo percutaneous coronary intervention ( attempt ) Combo stent placement . Registry Design : The REMEDEE REGISTRY international , prospective , multicenter , cohort post market registry five year follow-up evaluate outcome patient undergo percutaneous coronary intervention ( attempt ) Combo stent placement . The registry population consist consecutive patient treatment Combo stent set routine clinical care attempt . This registry involve collection baseline demographic , clinical , angiographic data , well follow-up data consecutive patient Combo stent use treat ( ) coronary lesion ( ) set routine clinical care . Patients register 10 European high volume PCI center . A follow-up scheduled 30 day , 180 days,1 year , 2 year , 3 year , 4 year 5 year post procedure . Follow-up obtain plan regular visit out-patient clinic , telephone contact patient . Quality control : All data enter on-site electronic case report ( eCRF ) form accord Good Clinical Practice guideline . All site monitor regularly time registry . The monitor plan involve hundred percent procedural information event monitoring . During data monitoring , source data assess accuracy , completeness , representativeness registry data compare data external data source . Data check compare data enter registry predefined rule range consistency data field registry implement ( eCRF ) . A data dictionary contains detailed description variable used registry , include source variable , cod information use , normal range relevant part database eCRF design . Standard Operating Procedures address registry operation analysis activity , patient recruitment , data collection , data management , data analysis , report adverse event , change management place . A detailed statistical analysis plan describe analytical principle statistical technique employ order address primary secondary objective , specify study protocol available . Missing data account design eCRF template , handle accord statistical plan .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Consecutive patient eligible Combo stent placement percutaneous coronary intervention include REMEDEE REGISTRY High probability nonadherence followup requirement ( due social , psychological medical reason ) Currently participate another investigational drug device study routine angiographic followup plan A life expectancy &lt; 1 year Explicit refusal participation registry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Stents</keyword>
	<keyword>Stent</keyword>
	<keyword>Drug elute</keyword>
	<keyword>Drug elute stent</keyword>
	<keyword>Drug elute stent</keyword>
	<keyword>Endothelial progenitor cell</keyword>
	<keyword>Endothelial progenitor cell capture</keyword>
	<keyword>Sirolimus</keyword>
	<keyword>Sirolimus elute</keyword>
	<keyword>Percutaneous Coronary Intervention</keyword>
	<keyword>PCI</keyword>
	<keyword>Registry</keyword>
	<keyword>Registries</keyword>
	<keyword>Multi center</keyword>
	<keyword>Multi centre</keyword>
</DOC>